drugset / Trial / NCT07697586
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multi-center, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with NSCLC. The study includes a dose escalation phase and an expansion phase.
Timeline
- Start
- 2026-08
- Primary completion
- 2028-08
- Completion
- 2029-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SKB118 | Unknown | 3 mg/kg | Intravenous |
| Subject | SKB118 | Unknown | 10 mg/kg | Intravenous |
| Subject | SKB118 | Unknown | 20 mg/kg | Intravenous |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 4 mg/kg | Intravenous |